Allon Therapeutics IncGrey Market:NPCUF
- LAST PRICE0.0001
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close--- / 0.0001
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Allon Therapeutics Inc | 14.1K | 0.0x | --- |
RenovaCare Inc | 90.0 | 0.0x | --- |
Regnum Corp | 20.0 | 0.0x | --- |
Cantabio Pharmaceuticals Inc | 22.8K | 0.0x | --- |
Miravant Medical Technologies | 40.0 | 0.0x | --- |
Evolutionary Genomics Inc | 5.3K | 0.0x | --- |
Company Information
Allon Therapeutics, Inc. is a Canada-based Company, which develops treatments for neurodegenerative diseases. The Company is engaged in pre-clinical and clinical development of proprietary neuroprotective compounds which may be applied for the potential treatment of Alzheimer's Disease, Parkinson's Disease, senile dementia, glaucoma, traumatic head injury, neuronal damage due to stroke and other conditions involving neurodegeneration. The Company's drug, davunetide, is proceeding in a pivotal Phase 2/3 clinical trial in an orphan indication, progressive supranuclear palsy (PSP), under a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA).
Contact Information
- Headquarters
- 1168 Hamilton St Suite 506VANCOUVER, BC, Canada V6B 2S2
- Phone
- 604-734-5060
- Fax
- 604-734-5060
Executives
- Independent Chairman of the Board
- James Miller
- President, Chief Executive Officer, Director
- Gordon McCauley
- Chief Financial Officer, Vice President - Finance, Secretary
- Matthew Carlyle
- Vice President - Drug Development
- Bruce Morimoto
- Vice President - Commercial Research
- Alistair Stewart
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $14.1K |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 141.1M |
Allon Therapeutics Inc does not pay a dividend. | |
Beta | --- |
EPS | $-0.07 |
Book Value | $0.00 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
